BIOCRYST PHARMACEUTICALS, INC. Finance Lease, Right-of-Use Asset, Amortization
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Finance Lease, Right-of-Use Asset, Amortization of $366.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $366.00K, a 33.94% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $377.00K, a 29.93% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $460.00K, a 5.74% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $547.00K, a 20.22% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $2.10M, a 18.86% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $1.77M, a 45.71% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $1.21M, a 48.53% increase from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $816.00K, a 622.12% increase from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $366.00K 10-Q · filed 2026-08-05 | $743.00K 10-Q · filed 2026-08-05 | $1.20M derived: sum of 3 quarters · filed 2026-08-05 | $1.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $377.00K 10-Q · filed 2026-05-06 | $837.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.38M derived: sum of 3 quarters · filed 2026-05-06 | $1.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.01M derived: sum of 2 quarters · filed 2026-02-26 | $1.56M derived: sum of 3 quarters · filed 2026-08-05 | $2.10M 10-K · filed 2026-02-26 |
| 2025-09-30 | $547.00K 10-Q · filed 2025-11-04 | $1.10M derived: sum of 2 quarters · filed 2026-08-05 | $1.64M 10-Q · filed 2025-11-04 | $2.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $554.00K 10-Q · filed 2026-08-05 | $1.09M 10-Q · filed 2026-08-05 | $1.58M derived: sum of 3 quarters · filed 2026-08-05 | $2.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $538.00K 10-Q · filed 2026-05-06 | $1.03M derived: sum of 2 quarters · filed 2026-05-06 | $1.48M derived: sum of 3 quarters · filed 2026-05-06 | $1.90M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $488.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $943.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.36M derived: sum of 3 quarters · filed 2026-02-26 | $1.77M 10-K · filed 2026-02-26 |
| 2024-09-30 | $455.00K 10-Q · filed 2025-11-04 | $871.00K derived: sum of 2 quarters · filed 2025-11-04 | $1.28M 10-Q · filed 2025-11-04 | $1.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $416.00K 10-Q · filed 2025-08-05 | $823.00K 10-Q · filed 2025-08-05 | $1.21M derived: sum of 3 quarters · filed 2026-02-26 | $1.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $407.00K 10-Q · filed 2025-05-06 | $796.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.10M derived: sum of 3 quarters · filed 2026-02-26 | $1.36M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $389.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $689.00K derived: sum of 2 quarters · filed 2026-02-26 | $956.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.21M 10-K · filed 2026-02-26 |
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-05 | $567.00K derived: sum of 2 quarters · filed 2024-11-05 | $823.00K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $267.00K 10-Q · filed 2024-08-06 | $523.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $256.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $816.00K 10-K · filed 2025-02-25 | |||
| 2021-12-31 | $113.00K 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |